BBI Brickell Biotech

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
Company profile
Ticker
BBI
Exchange
Website
CEO
Robert Brown
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
Former names
VICAL INC, VICAL, INC.
SEC CIK
Corporate docs
IRS number
930948554
BBI stock data
()
News
12 Health Care Stocks Moving In Monday's After-Market Session
12 Apr 21
50 Biggest Movers From Yesterday
19 Mar 21
12 Health Care Stocks Moving In Thursday's Intraday Session
18 Mar 21
38 Stocks Moving In Thursday's Mid-Day Session
18 Mar 21
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Mar 21
Press releases
Thinking about buying stock in Can Fite Biopharma, Aytu Bioscience, Hall of Fame Resort & Entertainment, Brickell Biotech, or Infinity Pharmaceuticals?
18 Mar 21
Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
9 Mar 21
Brickell Biotech Inc to Host Earnings Call
9 Mar 21
Brickell Biotech to Participate in March Virtual Investor Conferences
25 Feb 21
Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021
23 Feb 21
Calendar
9 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 30.12M | 30.12M | 30.12M | 30.12M | 30.12M | 30.12M |
Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 2.47M | 1.75M | 1.58M | 1.67M |
Cash used (since last report) | n/a | n/a | 8.5M | 6.02M | 5.45M | 5.75M |
Cash remaining | n/a | n/a | 21.62M | 24.1M | 24.66M | 24.37M |
Runway (months of cash) | n/a | n/a | 8.8 | 13.8 | 15.6 | 14.6 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Mar 21 | McAvoy David R. | Common Stock | Payment of exercise | Dispose F | No | No | 1.14 | 8,750 | 9.98K | 92,133 |
16 Mar 21 | McAvoy David R. | Common Stock | Option exercise | Aquire M | No | No | 0 | 25,000 | 0 | 100,883 |
16 Mar 21 | McAvoy David R. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 25,000 | 0 | 0 |
16 Mar 21 | Sklawer Andrew D | Common Stock | Payment of exercise | Dispose F | No | No | 1.14 | 7,000 | 7.98K | 109,250 |
16 Mar 21 | Sklawer Andrew D | Common Stock | Option exercise | Aquire M | No | No | 0 | 20,000 | 0 | 116,250 |
16 Mar 21 | Sklawer Andrew D | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 20,000 | 0 | 0 |
16 Mar 21 | Breton Jose | Common Stock | Payment of exercise | Dispose F | No | No | 1.14 | 5,250 | 5.98K | 11,919 |
16 Mar 21 | Breton Jose | Common Stock | Option exercise | Aquire M | No | No | 0 | 15,000 | 0 | 17,169 |
16 Mar 21 | Breton Jose | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 15,000 | 0 | 0 |
16 Mar 21 | Chadha Deepak | Common Stock | Payment of exercise | Dispose F | No | No | 1.14 | 8,750 | 9.98K | 62,967 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|
Financial report summary
?Competition
Pfizer • Astrazeneca • Sanofi • Scynexis • Genocea Biosciences • Abbvie • Cidara Therapeutics • Amplyx PharmaceuticalsRisks
- Our business depends on the successful financing, clinical development, regulatory approval, and commercialization of sofpironium bromide.
- We have never conducted a pivotal Phase 3 clinical trial ourselves and may be unable to successfully do so for sofpironium bromide.
- Clinical drug development for sofpironium bromide is expensive, time-consuming, and uncertain.
- Use of PROs and gravimetric assessments in sofpironium bromide clinical trials may delay or adversely impact the development of sofpironium bromide gel or clinical trial results or increase our development costs.
- Sofpironium bromide may cause undesirable side effects or have other unexpected properties that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action.
- Under our Clinical Supply Agreement with Kaken, our inability to obtain such API from Kaken on a timely basis could have a material adverse impact on our business.
- Kaken substantially controls the development and commercialization of sofpironium bromide in Japan and certain other Asian countries and may make decisions regarding product development, regulatory strategy, and commercialization that may not be in our best interests. Kaken may be unable to secure an appropriate local business partner (if desirable) and/or obtain approval of the drug in the ex-Japan Asian markets over which it has rights.
- If we or any partners with which we may collaborate to market and sell sofpironium bromide are unable to achieve and maintain medical insurance coverage and adequate levels of reimbursement for this compound following regulatory approval and usage by patients, our commercial success may be hindered severely.
- Major public health issues, and specifically the pandemic caused by the spread of COVID-19 and COVID-19 variants that are recently emerging, could have an adverse impact on our financial condition and results of operations and other aspects of our business and that of our suppliers, contractors, and business partners.
- Sofpironium bromide, if approved, will face significant competition and its failure to compete effectively may prevent it from achieving significant market penetration.
- We may face generic competition for sofpironium bromide, which could expose us to litigation or adversely affect our business, financial condition, operating results, and prospects.
- We currently have limited marketing capabilities and no sales organization. If we are unable to establish sales and marketing capabilities on our own or through third parties, or are delayed in establishing these capabilities, we will be unable to successfully commercialize our product candidates, if approved, or generate product revenue.
- Our collaboration with AnGes may prove to be unsuccessful, either because AnGes is unable to timely develop its COVID-19 vaccine candidate, or because we are not able to continue with this alliance for a variety of business, financial, or other reasons.
- Our business and operations would suffer in the event of system failures, cyber-attacks, or a deficiency in our cyber-security.
- We may be adversely affected by natural disasters and other catastrophic events and by man-made problems such as war or terrorism or labor disruptions that could disrupt our business operations, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
- We will need to raise substantial additional financing in the future to fund our operations and/or prepare an NDA submission in the U.S. for sofpironium bromide, which may not be available to us on favorable terms or at all.
- Our operating results and liquidity needs could be affected negatively by global market fluctuations and economic downturns.
- Our stock price and volume of shares traded have been and may continue to be highly volatile, and our common stock may continue to be illiquid.
- Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.
- We are a “smaller reporting company” and the reduced disclosure and governance requirements applicable to smaller reporting companies may make our common stock less attractive to some investors.
- If the holders of our company’s stock options and warrants exercise their rights to purchase our common stock, the ownership of our stockholders will be diluted.
- We may not be able to access the full amounts available under the Purchase Agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which could prevent us from accessing the capital we need to continue our operations, which could have an adverse effect on our business.
- Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our common stock.
- We do not anticipate paying any dividends in the foreseeable future.
- Our ability to use our net operating loss carryforwards and other tax assets to offset future taxable income may be subject to certain limitations.
- We have sponsored or supported and may in the future sponsor or support clinical trials for our product candidates outside the U.S. and Japan, and the FDA, PMDA, and applicable foreign regulatory authorities may not accept data from such trials; in addition, we may not be allowed alone or with local country business partners to obtain regulatory approval for our product candidates without first conducting clinical trials in each of these other countries.
- We may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.
- Our employees, independent contractors, principal investigators, other clinical trial staff, consultants, vendors, CROs, and any partners with which we may collaborate may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- We may be subject to risks related to pre-approval promotion or off-label use, or unauthorized direct-to-consumer advertising, of our product candidates.
- Healthcare reform measures, including price controls or restricted access, could hinder or prevent the commercial success of our product candidates.
- We also may be subject to stricter healthcare laws, regulation, and enforcement, and our failure to comply with those laws could expose us to liability or adversely affect our business, financial condition, operating results, and prospects.
- We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.
- We intend to in-license and acquire product candidates and may engage in other strategic transactions, which could impact our liquidity, increase our expenses, and present significant distractions to our management.
- Our failure to in-license, acquire, develop, and market successfully additional product candidates or approved products would impair our ability to grow our business.
- Other than sofpironium bromide, our other product candidates are at the early stages of clinical and regulatory development.
- We may choose not to continue developing or commercializing any of our early-stage product candidates, or to pursue the AnGes collaboration regarding a COVID-19 vaccine, at any time during development or after approval, which would reduce or eliminate our potential return on investment for those product candidates.
- We expect to rely on our collaboration with third-party out-license partners for the successful development and commercialization of our product candidates.
- We rely completely on third-party contractors to supply, manufacture, and distribute clinical drug supplies for our product candidates, including certain sole-source suppliers and manufacturers; we intend to rely on third parties for commercial supply, manufacturing, and distribution if any of our product candidates receive regulatory approval; and we expect to rely on third parties for supply, manufacturing, and distribution of preclinical, clinical, and commercial supplies of any future product candidates.
- Manufacturing and supply of the APIs and other substances and materials used in our product candidates and finished drug products is a complex and technically challenging undertaking, and there is potential for failure at many points in the manufacturing, testing, quality control and assurance and distribution supply chain, as well as the potential for latent defects after products have been manufactured and distributed.
- We may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover sofpironium bromide and related technologies (and any other product candidates) that are of sufficient breadth and term.
- We may not be able to protect our intellectual property rights throughout the world.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent and similar agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
- If we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are important to our business. Additionally, these agreements may be subject to disagreement over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.
- We may be subject to claims that our employees, officers, directors, advisors, consultants, or independent contractors have wrongfully used or disclosed to us alleged trade secrets or other confidential and proprietary information of their former employers or their former or current partners or customers.
- Provisions of Delaware law and our restated certificate of incorporation and amended and restated bylaws may discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management.
- If we fail to attract and retain management and other key personnel and directors, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan.
Management Discussion
- ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
- We are a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on our lead asset for the treatment of hyperhidrosis. Our executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, and Juvederm®.
- Our pivotal Phase 3 clinical-stage investigational product candidate, sofpironium bromide, is a new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action locally and are potentially rapidly metabolized to a less active form once absorbed into the blood. This proposed mechanism of action may allow for potentially highly effective doses to be used while limiting systemic side effects. We intend to develop sofpironium bromide as a potential best-in-class, self-administered, once daily, topical therapy for the treatment of primary axillary (underarm) hyperhidrosis.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abbreviated, AbbVie, absorption, acne, aesthetic, Africa, aka, Albert, allegedly, Alpharma, ancillary, ANDA, Andrew, annum, Baruch, Belgium, BELLAFILL, beneficiary, Berhampur, Bernard, bid, bioequivalence, BioScience, black, Book, bottle, bound, box, BPCA, breast, Breton, Brown, carcinogenicity, Cardigan, cardiology, career, cGCP, Chadha, championing, cheaper, China, clarify, Client, CMC, commented, conceive, Concordia, confirmatory, Connecticut, consecutive, counsel, CPP, crystalline, CTA, CTMX, cyber, cybersecurity, CytomX, Dame, Danforth, decentralized, Delhi, delisted, delisting, Deloitte, DePauw, depression, detect, detected, dispensing, dissemination, Dominguez, easily, East, ECCLOCK, Edge, Elanco, element, Eli, elongation, EMC, Endocyte, enzymatic, epidemic, exacerbated, exempt, Exemption, explanation, exploratory, fashion, FDC, filler, FIU, Florida, France, Franklin, FSC, gram, greatly, guide, Hamdard, hand, hospital, IberiaBank, Inamed, Indiana, indirect, inflating, instance, Intercontinental, interventional, irreversible, Japanese, Kadmon, KYBELLA, KYTHERA, language, Lilly, LLY, Marchio, McAvoy, MedPointe, Miami, Middle, min, molecule, monetization, movement, Muhlenberg, NCE, neurodegenerative, Nevada, NHI, nightly, nonperformance, Notre, nuclear, NYSE, offeror, Omitted, oncology, Oppenheimer, optimum, Orange, Orissa, overlap, pancreatic, panel, pattern, paused, Paycheck, payroll, PDS, pharmacological, pharmacology, phishing, plastic, political, polymorphic, PPACA, PPP, practitioner, preemption, premature, preying, prioritization, problematic, prohibitory, punishable, quarantine, rarer, realistically, reconsider, regained, region, ReoPro, repayment, reproductive, rest, resubmission, Robert, Rockabye, RSU, salesforce, sanctioned, scar, scarcity, Secretary, segregate, send, sequential, Silicone, skipped, Sklawer, spread, StartUp, streamline, strict, subpopulation, Suneva, supplement, switched, temporarily, Thirteen, Treasurer, unannounced, underpayment, USA, USD, user, Valley, Verid, vi, Victory, viii, waiting, withdrawn, York
Removed:
advanced, advancement, American, announced, assuming, calendar, certified, compare, conserve, consisting, cure, derived, developmental, enhance, enterprise, formula, impaired, Institute, intangible, invalidate, modification, necessarily, nonrefundable, nonstatutory, objective, provisional, quarterly, realization, repeal, represent, representing, retrospective, shared, sharing, spend, terminating, twelve, unaudited, VICL, vigorously
Financial reports
10-K
2020 FY
Annual report
9 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
12 Aug 20
10-Q
2020 Q1
Quarterly report
13 May 20
10-K
2019 FY
Annual report
18 Mar 20
10-Q
2019 Q3
Quarterly report
13 Nov 19
10-Q
2019 Q2
Quarterly report
12 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K/A
2018 FY
Annual report (amended)
17 Apr 19
10-K
2018 FY
Annual report
1 Mar 19
Current reports
8-K
Entry into a Material Definitive Agreement
9 Mar 21
8-K
Brickell Biotech Reports Fourth Quarter and Full Year 2020
9 Mar 21
8-K
Departure of Directors or Certain Officers
26 Feb 21
8-K
Regulation FD Disclosure
22 Jan 21
8-K
Departure of Directors or Certain Officers
24 Nov 20
8-K
Brickell Biotech Reports Third Quarter 2020 Financial Results
12 Nov 20
8-K
Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering
23 Oct 20
8-K
Regulation FD Disclosure
6 Oct 20
8-K
Japan is the first country to approve sofpironium bromide with commercial launch expected later this year
25 Sep 20
8-K
Departure of Directors or Certain Officers
1 Sep 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
17 Mar 21
S-3
Shelf registration
9 Mar 21
424B4
Prospectus supplement with pricing info
23 Oct 20
S-1/A
IPO registration (amended)
22 Oct 20
S-1/A
IPO registration (amended)
19 Oct 20
S-1
IPO registration
13 Oct 20
S-8
Registration of securities for employees
9 Sep 20
424B3
Prospectus supplement
13 Aug 20
424B4
Prospectus supplement with pricing info
18 Jun 20
S-1/A
IPO registration (amended)
17 Jun 20
Proxies
DEFA14A
Additional proxy soliciting materials
24 Mar 21
DEF 14A
Definitive proxy
15 Mar 21
PRE 14A
Preliminary proxy
2 Mar 21
DEF 14A
Definitive proxy
27 Jul 20
PRE 14A
Preliminary proxy
15 Jul 20
DEFA14A
Additional proxy soliciting materials
3 Apr 20
DEF 14A
Definitive proxy
30 Mar 20
PRE 14A
Preliminary proxy
18 Mar 20
DEFA14A
Additional proxy soliciting materials
23 Aug 19
DEFA14A
Additional proxy soliciting materials
21 Aug 19
Other
EFFECT
Notice of effectiveness
18 Mar 21
EFFECT
Notice of effectiveness
23 Oct 20
CORRESP
Correspondence with SEC
19 Oct 20
CORRESP
Correspondence with SEC
19 Oct 20
UPLOAD
Letter from SEC
15 Oct 20
EFFECT
Notice of effectiveness
18 Jun 20
CORRESP
Correspondence with SEC
15 Jun 20
CORRESP
Correspondence with SEC
15 Jun 20
UPLOAD
Letter from SEC
21 May 20
EFFECT
Notice of effectiveness
29 Apr 20
Ownership
4
Brickell Biotech / Jose Breton ownership change
17 Mar 21
4
Brickell Biotech / Deepak Chadha ownership change
17 Mar 21
4
Brickell Biotech / David R. McAvoy ownership change
17 Mar 21
4
Brickell Biotech / Andrew D Sklawer ownership change
17 Mar 21
4
Brickell Biotech / Robert Busard Brown ownership change
17 Mar 21
SC 13G/A
Brickell Biotech / CVI Investments ownership change
16 Feb 21
SC 13G/A
Brickell Biotech / BIOTECHNOLOGY VALUE FUND L P ownership change
11 Feb 21
4
Brickell Biotech / REGINALD L HARDY ownership change
5 Jan 21
4
Brickell Biotech / GARY A LYONS ownership change
5 Jan 21
4
Brickell Biotech / VIJAY B SAMANT ownership change
5 Jan 21
Transcripts
Reddit threads
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - March 27, 2021
26 Mar 21
Daily Plays - March 24, 2021
24 Mar 21
My grandpas giving me $100 to invest in stocks.
20 Mar 21
$BBI - Brickell Biotech CEO just invested 118000 dollars into it and it's moving quite much in premarket
18 Mar 21
Daily Plays - March 18, 2021
18 Mar 21
Daily Discussion Thread - March 9th, 2021
9 Mar 21
Daily Plays - March 09, 2021
9 Mar 21
Daily Discussion Thread - March 8th, 2021
8 Mar 21
Anomalous Stocks, Monday, March 1, 2021
1 Mar 21
What Stock Do You Think Is Just Waiting To Explode In The Coming Years And Dominate It's Market?
28 Feb 21